Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases.
Recent advances in stem cell biology have transformed the understanding of cell physiology and developmental biology such that it can now play a more prominent role in the clinical application of stem cell and regenerative medicine. Success in the generation of human induced pluripotent stem cells (iPS) as well as related emerging technology on the iPS platform provide great promise in the development of regenerative medicine. Human iPS cells show almost identical properties to human embryonic stem cells (ESC) in pluripotency, but avoid many of their limitations of use. In addition, investigations into reprogramming of somatic cells to pluripotent stem cells facilitate a deeper understanding of human stem cell biology. The iPS cell technology has offered a unique platform for studying the pathogenesis of human disease, pharmacological and toxicological testing, and cell-based therapy. Nevertheless, significant challenges remain to be overcome before the promise of human iPS cell technology can be realised.
Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, HKSAR, China.
Qizhou
Q
Lian
Yenyen
Y
Chow
Miguel Angel
MA
Esteban
Duanqing
D
Pei
Hung-Fat
HF
Tse
D000818:Animals; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D064987:Cell- and Tissue-Based Therapy / Q000639:trends; D004353:Drug Evaluation, Preclinical; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000378:metabolism* / Q000473:pathology; D044968:Regenerative Medicine